食管癌免疫检查点抑制剂临床应用全程管理专家共识OA北大核心CSTPCD

With the rapid development in the field of tumor immunotherapy,immune checkpoint inhibitors(ICIs)centered on programmed death-1(PD-1)and programmed death ligand-1(PD-L1)have made significant progress in the treatment of esophageal cancer.Several studies have confirmed the effectiveness and safety of ICIs in the treatment of esophageal cancer,and have gradually changed the landscape for treating advanced esophageal cancer.At present,ICIs have been widely used in the clinical treatment of esophageal cancer in China.In order to better guide the whole-process management of esophageal cancer ICIs application,improve the scientificity and standardization of esophageal cancer ICIs application,the China Anti-cancer Association Esophageal Tumor Integration Rehabilitation Professional Committee organized domestic experts in related fields to systematically sort out the latest domestic and foreign guidelines and evidence-based medical evidence through multiple rounds of discussions and revisions,and reach a consensus among expert in this review by fully considered the specific situation of clinical practice in China.